Altered LFTs (especially increased ALT) are frequently encountered in patients with type 2 diabetes as markers of hepatic steatosis and non-alcoholic fatty liver disease (NAFLD), along with markers of insulin resistance and dysfunctional adipose tissue [10–12]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.